Leerink Swann Analysts Cut Earnings Estimates for Spark Therapeutics Inc (ONCE)

Spark Therapeutics Inc (NASDAQ:ONCE) – Stock analysts at Leerink Swann reduced their FY2018 earnings per share (EPS) estimates for Spark Therapeutics in a report issued on Tuesday, November 6th. Leerink Swann analyst J. Schwartz now expects that the biotechnology company will earn ($0.74) per share for the year, down from their previous forecast of $0.34. Leerink Swann currently has a “Market Perform” rating and a $55.00 target price on the stock. Leerink Swann also issued estimates for Spark Therapeutics’ Q4 2018 earnings at ($0.37) EPS, Q1 2019 earnings at ($1.16) EPS, Q2 2019 earnings at ($0.95) EPS, Q3 2019 earnings at ($0.79) EPS, Q4 2019 earnings at ($0.70) EPS, FY2019 earnings at ($3.56) EPS and FY2020 earnings at ($4.59) EPS.

ONCE has been the topic of a number of other research reports. Guggenheim assumed coverage on shares of Spark Therapeutics in a report on Tuesday, October 9th. They set a “buy” rating and a $70.00 price target on the stock. Chardan Capital raised their price target on shares of Spark Therapeutics from $60.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, August 8th. Cantor Fitzgerald set a $103.00 price target on shares of Spark Therapeutics and gave the company a “buy” rating in a report on Monday, July 16th. Zacks Investment Research downgraded shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. Finally, Royal Bank of Canada dropped their price target on shares of Spark Therapeutics to $64.00 and set a “sector perform” rating on the stock in a report on Wednesday, August 8th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $68.52.

Shares of NASDAQ ONCE opened at $46.00 on Thursday. The stock has a market cap of $1.57 billion, a PE ratio of -6.03 and a beta of 2.27. Spark Therapeutics has a 52-week low of $39.01 and a 52-week high of $96.59.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.22). The company had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $27.44 million. Spark Therapeutics had a negative net margin of 127.82% and a negative return on equity of 14.34%. The business’s revenue was up 463.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.90) EPS.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Aperio Group LLC boosted its holdings in shares of Spark Therapeutics by 23.5% in the second quarter. Aperio Group LLC now owns 5,543 shares of the biotechnology company’s stock worth $459,000 after buying an additional 1,056 shares during the last quarter. Tocqueville Asset Management L.P. boosted its holdings in shares of Spark Therapeutics by 2.7% in the second quarter. Tocqueville Asset Management L.P. now owns 41,225 shares of the biotechnology company’s stock worth $3,412,000 after buying an additional 1,075 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of Spark Therapeutics by 29.7% in the second quarter. Amalgamated Bank now owns 4,799 shares of the biotechnology company’s stock worth $397,000 after buying an additional 1,100 shares during the last quarter. Smith Asset Management Group LP boosted its holdings in shares of Spark Therapeutics by 39.6% in the third quarter. Smith Asset Management Group LP now owns 3,950 shares of the biotechnology company’s stock worth $215,000 after buying an additional 1,120 shares during the last quarter. Finally, Capital Fund Management S.A. raised its stake in Spark Therapeutics by 8.1% during the 2nd quarter. Capital Fund Management S.A. now owns 15,379 shares of the biotechnology company’s stock worth $1,273,000 after acquiring an additional 1,152 shares during the period.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

See Also: How Do Tariffs Affect Trade Balances?

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply